Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN P G 165 versus MICONAZOLE NITRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN P G 165 versus MICONAZOLE NITRATE.
FULVICIN P/G 165 vs MICONAZOLE NITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Griseofulvin binds to and disrupts microtubule function by inhibiting spindle formation and mitosis in dermatophytes, leading to inhibition of fungal cell division.
Inhibits fungal CYP450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
165 mg orally once daily.
Topical: Apply twice daily for 2-4 weeks. Vaginal: 200 mg suppository at bedtime for 3 days, or 100 mg suppository at bedtime for 7 days, or 1200 mg suppository as a single dose. Oral (buccal): 50 mg once daily for 14 days.
None Documented
None Documented
Terminal elimination half-life is approximately 9-24 hours; dependent on formulation and absorption rate. Steady-state achieved within 4-5 days.
Terminal elimination half-life is approximately 24 hours (range 20-40 hours) following intravenous administration. This extended half-life supports twice-daily dosing for systemic infections.
Primarily renal excretion of metabolites; <1% excreted unchanged. Biliary/fecal elimination accounts for ~30% of metabolites.
Miconazole is primarily metabolized in the liver, with less than 1% of an intravenous dose excreted unchanged in urine. Biliary/fecal elimination accounts for approximately 50% of the dose as metabolites. Renal elimination of metabolites is minimal.
Category C
Category A/B
Antifungal
Antifungal